These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

577 related articles for article (PubMed ID: 25982279)

  • 1. Targeting JAK kinase in solid tumors: emerging opportunities and challenges.
    Buchert M; Burns CJ; Ernst M
    Oncogene; 2016 Feb; 35(8):939-51. PubMed ID: 25982279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
    Lai SY; Johnson FM
    Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.
    Bharadwaj U; Kasembeli MM; Robinson P; Tweardy DJ
    Pharmacol Rev; 2020 Apr; 72(2):486-526. PubMed ID: 32198236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The JAK/STAT3 axis: A comprehensive drug target for solid malignancies.
    Huynh J; Etemadi N; Hollande F; Ernst M; Buchert M
    Semin Cancer Biol; 2017 Aug; 45():13-22. PubMed ID: 28647610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The IL-6/JAK/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (Review).
    Wang SW; Sun YM
    Int J Oncol; 2014 Apr; 44(4):1032-40. PubMed ID: 24430672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases.
    Murone M; Vaslin Chessex A; Attinger A; Ramachandra R; Shetty SJ; Daginakatte G; Sengupta S; Marappan S; Dhodheri S; Rigotti S; Bachhav Y; Brienza S; Traxler P; Lang M; Aguet M; Zoete V; Michielin O; Nicholas C; Johnson FM; Ramachandra M; McAllister A
    Mol Cancer Ther; 2016 Oct; 15(10):2334-2343. PubMed ID: 27439479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.
    Wen W; Wu J; Liu L; Tian Y; Buettner R; Hsieh MY; Horne D; Dellinger TH; Han ES; Jove R; Yim JH
    Mol Cancer; 2015 May; 14():100. PubMed ID: 25928246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The many faces of Janus kinase.
    Seavey MM; Dobrzanski P
    Biochem Pharmacol; 2012 May; 83(9):1136-45. PubMed ID: 22209716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the IL-6/JAK/STAT3 signalling axis in cancer.
    Johnson DE; O'Keefe RA; Grandis JR
    Nat Rev Clin Oncol; 2018 Apr; 15(4):234-248. PubMed ID: 29405201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK/STAT pathway plays a critical role in the proinflammatory gene expression and apoptosis of RAW264.7 cells induced by trichothecenes as DON and T-2 toxin.
    Wang X; Liu Q; Ihsan A; Huang L; Dai M; Hao H; Cheng G; Liu Z; Wang Y; Yuan Z
    Toxicol Sci; 2012 Jun; 127(2):412-24. PubMed ID: 22454431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zelnorm, an agonist of 5-Hydroxytryptamine 4-receptor, acts as a potential antitumor drug by targeting JAK/STAT3 signaling.
    Zhang L; Song Q; Zhang X; Li L; Xu X; Xu X; Li X; Wang Z; Lin Y; Li X; Li M; Su F; Wang X; Qiu P; Guan H; Tang Y; Xu W; Yang J; Zhao C
    Invest New Drugs; 2020 Apr; 38(2):311-320. PubMed ID: 31087223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
    Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL
    Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brevilin A, a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells.
    Chen X; Du Y; Nan J; Zhang X; Qin X; Wang Y; Hou J; Wang Q; Yang J
    PLoS One; 2013; 8(5):e63697. PubMed ID: 23704931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective JAK/STAT3 signalling regulates transcription of colony stimulating factor-2 and -3 in Concanavalin-A-activated mesenchymal stromal cells.
    Zgheib A; Pelletier-Bonnier É; Levros LC; Annabi B
    Cytokine; 2013 Aug; 63(2):187-93. PubMed ID: 23688618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK kinases overexpression promotes in vitro cell transformation.
    Knoops L; Hornakova T; Royer Y; Constantinescu SN; Renauld JC
    Oncogene; 2008 Mar; 27(11):1511-9. PubMed ID: 17873904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 17-hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3 signaling by covalently cross-linking Janus kinases and induces apoptosis of human cancer cells.
    Wang Y; Ma X; Yan S; Shen S; Zhu H; Gu Y; Wang H; Qin G; Yu Q
    Cancer Res; 2009 Sep; 69(18):7302-10. PubMed ID: 19706767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of the JAK-STAT3 pathway is associated with the growth of colorectal carcinoma cells.
    Wei X; Wang G; Li W; Hu X; Huang Q; Xu K; Lou W; Wu J; Liang C; Lou Q; Qian C; Liu L
    Oncol Rep; 2014 Jan; 31(1):335-41. PubMed ID: 24253664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell density dependent increase of constitutive signal transducers and activators of transcription 3 activity in melanoma cells is mediated by Janus kinases.
    Kreis S; Munz GA; Haan S; Heinrich PC; Behrmann I
    Mol Cancer Res; 2007 Dec; 5(12):1331-41. PubMed ID: 18171991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-angiogenic activity of thienopyridine derivative LCB03-0110 by targeting VEGFR-2 and JAK/STAT3 Signalling.
    Kim BH; Lee Y; Yoo H; Cui M; Lee S; Kim SY; Cho JU; Lee H; Yang BS; Kwon YG; Choi S; Kim TY
    Exp Dermatol; 2015 Jul; 24(7):503-9. PubMed ID: 25808463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis.
    Alas S; Bonavida B
    Clin Cancer Res; 2003 Jan; 9(1):316-26. PubMed ID: 12538484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.